Ocular Therapeutix Sets a New Standard in Retina Care with Bold Rebranding
BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL), a pioneering biopharmaceutical firm dedicated to transforming the retina treatment landscape, proudly unveils its innovative corporate branding and website. This launch marks a significant milestone as the company embarks on its journey to become a leader in retinal therapies.
Rebranding with Purpose: A Vision for the Future
Ocular Therapeutix Logo
At the heart of the new logo is a commitment to visual accessibility, grounded in science and infused with joy. The circular ‘O’ symbolizes the eye and retina, while a vibrant, full-spectrum color palette evokes the richness of human vision. The stylized ‘X’ signifies the intersection between past achievements and future ambitions.
Innovative Leadership: A Message from the CEO
“Retinal diseases, such as wet age-related macular degeneration (AMD), are among the leading causes of blindness,” states Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix. “Our mission is to redefine the retina experience, alleviating the burden of treatment to help preserve vision over time. This rebranding encapsulates the significant progress we’ve made, fueled by our dedication to our patients and the momentum generated by our SOL trials.”
Disrupting the Status Quo in Retinal Treatments
Ocular Therapeutix Anthem Video
Ocular Therapeutix: Retina Experience Redefined
Unity of Purpose: Significant Impact on Patients
Ocular Therapeutix is on a mission to revolutionize the treatment of retinal diseases, starting with wet AMD, which currently affects approximately 1.8 million people in the U.S. alone. Traditional treatment modalities often involve up to 12 injections per year, creating a substantial burden for both patients and caregivers. Shockingly, one in four patients may develop fibrosis within two years, with risks of atrophy increasing over five years.
Enter Ocular’s investigational therapy, AXPAXLI™ (also known as OTX-TKI), an axitinib hydrogel administered through intravitreal injection. This groundbreaking treatment has the potential to enhance the durability and long-term outcomes for patients facing wet AMD and similar retinal disorders.
Welcoming the New Brand to the Global Stage
With the new corporate branding live across its website, social media platforms, and internal channels, Ocular Therapeutix is poised to make a significant splash at the upcoming American Society of Retina Specialists (ASRS) conference. This event will be a defining moment as they present this exciting new chapter to the world.
Explore our captivating new corporate branding at our website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. stands as a fully-integrated biopharmaceutical company dedicated to redefining the retina experience. Their flagship product, AXPAXLI™ (also known as OTX-TKI), is currently advancing through Phase 3 clinical trials for wet age-related macular degeneration.
The Ocular pipeline also leverages its proprietary ELUTYX™ technology in the commercial product DEXTENZA®, an FDA-approved corticosteroid designed to treat ocular inflammation and pain post-ophthalmic surgery, along with an investigational candidate, OTX-TIC, currently in Phase 2 trials for open-angle glaucoma or ocular hypertension.
Stay connected with Ocular through their website, LinkedIn, or X.
Contact Information:
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
A photo accompanying this announcement can be found here.
